{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:17:35Z","timestamp":1790695055719,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background and aims<\/jats:title><jats:p>Recent studies suggest that empagliflozin reduces total and cardiovascular mortality in both diabetic and nondiabetic subjects. Although the exact mechanism is unclear, it is understood to positively affect myocardial energetics, including the metabolism of ketone bodies, lipids, and fatty acids. In this study, we compared empagliflozin effects on lipid metabolism in the heart and liver in a prediabetic rat model with severe dyslipidemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Wistar rats served as the control group, while hereditary hypertriglyceridemic (HHTg) rats were used as a nonobese, prediabetic model. Rats were treated with or without empagliflozin at a dose of 10\u00a0mg\/kg body weight (BW) for 8\u00a0weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In HHTg rats, empagliflozin decreased body weight and adiposity, improved glucose tolerance, and decreased serum triacylglycerols (TAGs) (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). Empagliflozin decreased the activity and gene expression of the lipogenic enzyme SCD-1 (<jats:italic>p<\/jats:italic> &amp;lt; 0.001) in the myocardium, which may have led to a decrease in the ectopic accumulation of TAGs and lipotoxic diacylglycerols and lysophosphatidylcholines (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). Changes in the myocardial phosphatidylcholine\/phosphatidylethanolamine ratio (<jats:italic>p<\/jats:italic> &amp;lt; 0.01) and in the fatty acid profile of myocardial phospholipids may have contributed to the antifibrotic effects of empagliflozin. The anti-inflammatory effects of empagliflozin were evidenced by an increased IL-10\/TNF\u03b1 ratio (<jats:italic>p<\/jats:italic> &amp;lt; 0.001), a marked decrease in arachidonic acid metabolites (20-HETE, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), and an increase in PUFA metabolites (14,15-EETs, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) in the myocardium. However, empagliflozin did not significantly affect either the concentration or utilization of ketone bodies. In the liver, empagliflozin decreased lipogenesis and the accumulation of TAGs and lipotoxic intermediates. Its effect on arachidonic acid metabolites and alterations in n-3 PUFA metabolism was less pronounced than in the myocardium.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings suggest that empagliflozin treatment in the heart and liver reduced the accumulation of neutral lipids and lipotoxic intermediates and altered the metabolism of n-3 PUFA. In the heart, empagliflozin altered arachidonic acid metabolism, which is likely associated with the anti-inflammatory and antifibrotic effects of the drug. We assume that these alterations in lipid metabolism contribute to the cardioprotective effects of empagliflozin in prediabetic states with severe dyslipidemia.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1393946","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T04:55:17Z","timestamp":1720068917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia"],"prefix":"10.3389","volume":"15","author":[{"given":"Denisa","family":"Miklankova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Markova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"H\u00fcttl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Malinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"113677","DOI":"10.1016\/j.bcp.2019.113677","article-title":"Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats","volume":"170","author":"Aragon-Herrera","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.3390\/ijms24065531","article-title":"Role of stearoyl-CoA desaturase 1 in cardiovascular physiology","volume":"24","author":"Balatskyi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e006573","DOI":"10.1161\/CIRCHEARTFAILURE.119.006573","article-title":"Chronically elevating circulating ketones can reduce cardiac inflammation and blunt the development of heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ. Heart Fail"},{"key":"B5","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jss.2020.11.087","article-title":"An optimized model of hypertrophic preconditioning confers cardioprotection in the mouse","volume":"264","author":"Cai","year":"2021","journal-title":"J. Surg. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"110072","DOI":"10.1016\/j.intimp.2023.110072","article-title":"New insights into the molecular mechanisms of SGLT2 inhibitors on ventricular remodeling","volume":"118","author":"Chen","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0284","DOI":"10.1097\/XCE.0000000000000284","article-title":"Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis","volume":"12","author":"Deshpande","year":"2023","journal-title":"Cardiovasc Endocrinol. Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0378-4347(95)00142-6","article-title":"Gas chromatographic analysis of fatty acid methyl esters","volume":"671","author":"Eder","year":"1995","journal-title":"J. Chromatogr. B Biomed. Appl."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1073\/pnas.0336724100","article-title":"A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content","volume":"100","author":"Finck","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/ijms24021408","article-title":"Dapagliflozin treatment augments bioactive phosphatidylethanolamine concentrations in kidney cortex membrane fractions of hypertensive diabetic db\/db mice and alters the density of lipid rafts in mouse proximal tubule cells","volume":"24","author":"Gholam","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1714\/3900.38825","article-title":"The mechanisms mediating the favorable effects of sodium-glucose cotransporter 2 inhibitors on cardiorenal function","volume":"23","author":"Gronda","year":"2022","journal-title":"G. Ital. Cardiol. (Rome)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/Glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"B15","doi-asserted-by":"publisher","first-page":"112246","DOI":"10.1016\/j.biopha.2021.112246","article-title":"Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension","volume":"144","author":"Hojna","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2020.5.04","article-title":"Metabolic cardio- and reno-protective effects of empagliflozin in a prediabetic rat model","volume":"71","author":"Huttl","year":"2020","journal-title":"J. Physiol. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"11513","DOI":"10.3390\/ijms222111513","article-title":"In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia","volume":"22","author":"Huttl","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.3390\/jcm8111814","article-title":"The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes","volume":"8","author":"Iannantuoni","year":"2019","journal-title":"J. Clin. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10741-008-9104-z","article-title":"Biology of TNFalpha and IL-10, and their imbalance in heart failure","volume":"14","author":"Kaur","year":"2009","journal-title":"Heart Fail Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"8534","DOI":"10.1002\/jcb.28141","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and \u03b1-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes","volume":"120","author":"Kim","year":"2018","journal-title":"J. Cell Biochem."},{"key":"B22","doi-asserted-by":"publisher","first-page":"104870","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin protects heart from inflammation and energy depletion via AMPK activation","volume":"158","author":"Koyani","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/MOL.0000000000000751","article-title":"Lipid effects of sodium-glucose cotransporter 2 inhibitors","volume":"32","author":"Lazarte","year":"2021","journal-title":"Curr. Opin. Lipidol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1093\/eurheartj\/ehv442","article-title":"Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus","volume":"37","author":"Levelt","year":"2016","journal-title":"Eur. Heart J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly","year":"2022","journal-title":"Diabetologia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.arteri.2017.07.004","article-title":"The impact of obesity in the cardiac lipidome and its consequences in the cardiac damage observed in obese rats","volume":"30","author":"Marin-Royo","year":"2018","journal-title":"Clin. Investig. Arterioscler."},{"key":"B27","doi-asserted-by":"publisher","first-page":"8712979","DOI":"10.1155\/2019\/8712979","article-title":"The effect of lipotoxicity on renal dysfunction in a nonobese rat model of metabolic syndrome: a urinary proteomic approach","volume":"2019","author":"Markova","year":"2019","journal-title":"J. Diabetes Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"7680","DOI":"10.3390\/ijms22147680","article-title":"Metformin affects cardiac arachidonic acid metabolism and cardiac lipid metabolite storage in a prediabetic rat model","volume":"22","author":"Miklankova","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE((-\/-)) mice by activating autophagy and reducing ER stress and apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e3047","DOI":"10.1002\/dmrr.3047","article-title":"Glycemic variability in the development of cardiovascular complications in diabetes","volume":"34","author":"Nusca","year":"2018","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","article-title":"Association between insulin resistance and the development of cardiovascular disease","volume":"17","author":"Ormazabal","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"110539","DOI":"10.1016\/j.mce.2019.110539","article-title":"Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress","volume":"498","author":"Petito-da-Silva","year":"2019","journal-title":"Mol. Cell Endocrinol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1476-511X-11-82","article-title":"Long-term treatment with the pan-PPAR agonist tetradecylthioacetic acid or fish oil is associated with increased cardiac content of n-3 fatty acids in rat","volume":"11","author":"Strand","year":"2012","journal-title":"Lipids Health Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/metabo11020087","article-title":"The effects of SGLT2 inhibitors on lipid metabolism","volume":"11","author":"Szekeres","year":"2021","journal-title":"Metabolites"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.bbamem.2017.04.006","article-title":"The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease","volume":"1859","author":"van der Veen","year":"2017","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"B39","first-page":"2579","article-title":"The hereditary hypertriglyceridemic nonobese rat: an experimental model of human hypertriglyceridemia","volume":"22","author":"Vrana","year":"1990","journal-title":"Transpl. Proc."},{"key":"B40","doi-asserted-by":"publisher","first-page":"999254","DOI":"10.3389\/fcvm.2022.999254","article-title":"Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy","volume":"9","author":"Xi","year":"2022","journal-title":"Front. Cardiovasc Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.3390\/jcm11216544","article-title":"Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu","volume":"11","author":"Yaribeygi","year":"2022","journal-title":"J. Clin. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1474-8673.2009.00426.x","article-title":"Role of 20-hydroxyeicosatetraenoic acid in altering vascular reactivity in diabetes","volume":"29","author":"Yousif","year":"2009","journal-title":"Auton. Autacoid Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3390\/ijms24010858","article-title":"Canagliflozin attenuates lipotoxicity in cardiomyocytes by inhibiting inflammation and ferroptosis through activating AMPK pathway","volume":"24","author":"Zhang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.33549\/physiolres.930000.55.S1.49","article-title":"Hereditary hypertriglyceridemic rat: a suitable model of cardiovascular disease and metabolic syndrome?","volume":"55","author":"Zicha","year":"2006","journal-title":"Physiol. Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/138920008783571792","article-title":"Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure","volume":"9","author":"Zordoky","year":"2008","journal-title":"Curr. Drug Metab."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1393946\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T04:55:22Z","timestamp":1720068922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1393946\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":46,"alternative-id":["10.3389\/fphar.2024.1393946"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1393946","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"article-number":"1393946"}}